Resmed Inc. Stock
Price
Target price
€214.80
€214.80
0.280%
0.6
0.280%
€215.00
15:37 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Resmed Inc. Stock
The Resmed Inc. stock is trending slightly upwards today, with an increase of €0.60 (0.280%) compared to yesterday's price.
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a current price of 214.8 € Resmed Inc. is right around the predicted target price of 215 €.
Pros and Cons of Resmed Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 0.280% | -6.667% | 3.628% | 56.693% | 36.651% | -12.105% | 78.292% |
| Waters Corp. | 1.420% | 0.840% | -3.348% | 15.462% | -0.596% | -11.183% | 45.340% |
| QuidelOrtho Corp. | 1.450% | 2.451% | 6.091% | -40.456% | -38.366% | -68.018% | -28.314% |
| Illumina Inc. | 3.090% | 4.114% | -0.304% | -11.485% | -8.233% | -69.058% | -57.065% |
Comments
ResMed Inc. (NYSE: RMD) had its "underperform" rating re-affirmed by analysts at Wolfe Research. They now have a $180.00 price target on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at KeyCorp from $238.00 to $251.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $236.00 price target on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Why ResMed Stock Tumbled by 5% Today
Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is
